Clinical trial
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating…
NCT00126594 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00126594 |
|---|---|
| Title | Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer |
| Official title | A Phase II Clinical Trial to Evaluate the Efficacy of BAY 43-9006 With or Without Low Dose Interferon in Metastatic Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | M.D. Anderson Cancer Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | Sorafenib Tosylate, Recombinant Interferon Alfa-2b, Laboratory Biomarker Analysis |
| Enrollment | 80 |
| Start date | Jun 1, 2005 |
| Primary completion | Aug 1, 2013 |
| Completion | Aug 1, 2013 |
| First posted | Aug 4, 2005 |
| Last update posted | Sep 16, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: